Cellebrite DI’s (CLBT) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Cellebrite DI (NASDAQ:CLBT) in a report published on Monday,Benzinga reports. They currently have a $28.00 price objective on the stock.

Several other equities research analysts have also recently weighed in on CLBT. JPMorgan Chase & Co. raised their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Lake Street Capital lifted their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $17.62 on Monday. The firm’s 50 day moving average price is $21.58 and its two-hundred day moving average price is $19.70. Cellebrite DI has a twelve month low of $10.25 and a twelve month high of $26.30. The firm has a market cap of $3.63 billion, a PE ratio of -12.68, a P/E/G ratio of 4.27 and a beta of 1.53.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Equities analysts anticipate that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently bought and sold shares of the stock. True Wind Capital Management L.P. increased its holdings in Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock worth $305,358,000 after acquiring an additional 2,130,386 shares during the last quarter. FMR LLC boosted its stake in Cellebrite DI by 89.1% in the 4th quarter. FMR LLC now owns 10,621,344 shares of the company’s stock worth $233,988,000 after purchasing an additional 5,004,587 shares during the period. Axon Enterprise Inc. bought a new position in Cellebrite DI in the 4th quarter worth about $198,270,000. Voss Capital LP boosted its stake in Cellebrite DI by 1.2% in the 4th quarter. Voss Capital LP now owns 3,240,000 shares of the company’s stock worth $71,377,000 after purchasing an additional 39,700 shares during the period. Finally, Pertento Partners LLP boosted its stake in Cellebrite DI by 26.7% in the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after purchasing an additional 626,373 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.